Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (NASDAQ: APGE), Sells Over $225,000 Worth of Company Stock
In a recent transaction, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics, Inc., sold a significant amount of company stock totaling over $225,000. The sales were conducted at varying prices, with two separate transactions executed on July 3, 2024.
The first sale involved 3,852 shares at an average price of $37.29 per share, while the second sale comprised 2,143 shares at an average price of $38.16 per share. These sales were carried out in accordance with a Rule 10b5-1 trading plan adopted on September 27, 2023, which allows company insiders to sell a predetermined number of shares at a predetermined time.
Following these transactions, Dambkowski's ownership in Apogee Therapeutics has been adjusted to reflect the reduced number of shares. Insider transactions like these can provide insights into an executive's view of the company's valuation and future prospects.
In other news, Apogee Therapeutics has been making significant strides in its clinical development programs, appointing Dr. Lisa Bollinger to its board of directors. Analysts have maintained a Buy rating on Apogee, citing optimism in the company's drug pipeline.
InvestingPro Insights:
- Market Cap: $2.19 billion USD
- Negative P/E ratio: -18.93
- One-year price total return: 79.09%
- Short-term price total return: -33.08%
- Cash exceeds debt on balance sheet
- Weak gross profit margins
- Not expected to be profitable this year
- Does not pay a dividend
For a more in-depth analysis and additional insights, check out InvestingPro Tips for Apogee Therapeutics. Use coupon code PRONEWS24 for up to 10% off a yearly subscription.